Estrogens and stem cells in thyroid cancer

Frontiers in Endocrinology

Volumn 5, Issue JUL, 2014, Pages

  Zane, Mariangela ^a,b   Catalano, Veronica ^a   Scavo, Emanuela ^a   Bonanno, Marco ^a   Pelizzo, Maria Rosa ^b   Todaro, Matilde ^a   Stassi, Giorgio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cancer stem cells; Estrogens; Growth factors; Stem cells; Thyroid cancer; Thyroid hormones

Indexed keywords

ADENYLATE CYCLASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTRIOL; ESTROGEN; ESTRONE; LIOTHYRONINE; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C; PROTIRELIN; RETINOID X RECEPTOR; THYROXINE;

CANCER RISK; CANCER STEM CELL; CELL DIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; DOWN REGULATION; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION; HUMAN; HYPOTHALAMUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID FUNCTION;

EID: 84905378689     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00124     Document Type: Short Survey

References (99)

1. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer (2006) 6:292-306. doi:10.1038/nrc1836
2. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn (2008) 8:83-95. doi:10.1586/14737159.8.1.83
3. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer (2009) 16:17-44. doi:10.1677/ERC-08-0154
4. Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. Future Oncol (2010) 6:1771-9. doi:10.2217/fon.10.127
5. Rajoria S, Suriano R, George AL, Shanmugam A, Jussim C, Shin EJ, et al. Estrogen activity as a preventive and therapeutic target in thyroid cancer. Biomed Pharmacother (2012) 66:151-8. doi:10.1016/j.biopha.2011.11.010
6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin (2013) 63:11-30. doi:10.3322/caac.21166
7. Rajoria S, Suriano R, Shanmugam A, Wilson YL, Schantz SP, Geliebter J, et al. Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid (2010) 20:33-41. doi:10.1089/thy.2009.0296
8. Xu S, Chen G, Peng W, Renko K, Derwahl M. Oestrogen action on thyroid progenitor cells: relevant for the pathogenesis of thyroid nodules? J Endocrinol (2013) 218:125-33. doi:10.1530/JOE-13-0029
9. Antico-Arciuch VG, Dima M, Liao XH, Refetoff S, Di Cristofano A. Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females. Oncogene (2010) 29:5678-86. doi:10.1038/onc.2010.308
10. Zeng Q, Chen GG, Vlantis AC, Van Hasselt CA. Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. Cell Prolif (2007) 40:921-35. doi:10.1111/j.1365-2184.2007.00471.x
11. Ceresini G, Milli B, Morganti S, Maggio M, Bacchi-Modena A, Sgarabotto MP, et al. Effect of estrogen therapy for 1 year on thyroid volume and thyroid nodules in postmenopausal women. Menopause (2008) 15:326-31. doi:10.1097/gme.0b013e318148b83e
12. Vaiman M, Olevson Y, Sandbank J, Habler L, Zehavi S, Kessler A. Are estrogen receptors alpha detectable in normal and abnormal thyroid tissue? Eur Arch Otorhinolaryngol (2010) 267:1753-7. doi:10.1007/s00405-010-1269-0
13. Takano T, Amino N. Fetal cell carcinogenesis: a new hypothesis for better understanding of thyroid carcinoma. Thyroid (2005) 15:432-8. doi:10.1089/thy.2005.15.432
14. Takano T. Fetal cell carcinogenesis of the thyroid: theory and practice. Semin Cancer Biol (2007) 17:233-40. doi:10.1016/j.semcancer.2006.02.001
15. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells - old concepts, new insights. Cell Death Differ (2008) 15:947-58. doi:10.1038/cdd.2008.20
16. Lin RY. Thyroid cancer stem cells. Nat Rev Endocrinol (2011) 7:609-16. doi:10.1038/nrendo.2011.127
17. Visvader JE. Cells of origin in cancer. Nature (2011) 469:314-22. doi:10.1038/nature09781
18. Todaro M, Iovino F, Eterno V, Cammareri P, Gambara G, Espina V, et al. Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res (2010) 70:8874-85. doi:10.1158/0008-5472.CAN-10-1994
19. Sastre-Perona A, Santisteban P. Role of the wnt pathway in thyroid cancer. Front Endocrinol (Lausanne) (2012) 3:31. doi:10.3389/fendo.2012.00031
20. Van Camp JK, Beckers S, Zegers D, Van Hul W. Wnt signaling and the control of human stem cell fate. Stem Cell Rev (2014) 10:207-29. doi:10.1007/s12015-013-9486-8
21. Nakada D, Oguro H, Levi BP, Ryan N, Kitano A, Saitoh Y, et al. Oestrogen increases haematopoietic stem-cell self-renewal in females and during pregnancy. Nature (2014) 505:555-8. doi:10.1038/nature12932
22. Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab (2001) 86:1072-7. doi:10.1210/jcem.86.3.7283
23. Lee ML, Chen GG, Vlantis AC, Tse GM, Leung BC, Van Hasselt CA. Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL. Cancer J (2005) 11:113-21. doi:10.1097/00130404-200503000-00006
24. Dong W, Zhang H, Li J, Guan H, He L, Wang Z, et al. Estrogen induces metastatic potential of papillary thyroid cancer cells through estrogen receptor alpha and beta. Int J Endocrinol (2013) 2013:941568. doi:10.1155/2013/941568
25. Santin AP, Furlanetto TW. Role of estrogen in thyroid function and growth regulation. J Thyroid Res (2011) 2011:875125. doi:10.4061/2011/875125
26. Arciuch Antico VG, Di Cristofano A. Estrogen signaling and thyrocyte proliferation. In: Ward DL, editor. Thyroid and Parathyroid Diseases - New Insights into Some Old and Some New Issues. InTech (2012). 318 p. doi:10.5772/35913
27. Thiruvengadam A, Govindarajulu P, Aruldhas MM. Modulatory effect of estradiol and testosterone on the development of N-nitrosodiisopropanolamine induced thyroid tumors in female rats. Endocr Res (2003) 29:43-51. doi:10.1081/ERC-120018675
28. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev (2007) 87:905-31. doi:10.1152/physrev.00026.2006
29. Zahid M, Goldner W, Beseler CL, Rogan EG, Cavalieri EL. Unbalanced estrogen metabolism in thyroid cancer. Int J Cancer (2013) 133:2642-9. doi:10.1002/ijc.28275
30. Huang Y, Dong W, Li J, Zhang H, Shan Z, Teng W. Differential expression patterns and clinical significance of estrogen receptor-alpha and beta in papillary thyroid carcinoma. BMC Cancer (2014) 14:383. doi:10.1186/1471-2407-14-383
31. Chu R, Van Hasselt A, Vlantis AC, Ng EK, Liu SY, Fan MD, et al. The cross-talk between estrogen receptor and peroxisome proliferator-activated receptor gamma in thyroid cancer. Cancer (2014) 120:142-53. doi:10.1002/cncr.28383
32. Leitman DC, Paruthiyil S, Vivar OI, Saunier EF, Herber CB, Cohen I, et al. Regulation of specific target genes and biological responses by estrogen receptor subtype agonists. Curr Opin Pharmacol (2010) 10:629-36. doi:10.1016/j.coph.2010.09.009
33. Klinge CM. Estrogen receptor interaction with co-activators and co-repressors. Steroids (2000) 65:227-51. doi:10.1016/S0039-128X(99)00107-5
34. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, et al. Mechanisms of estrogen action. Physiol Rev (2001) 81:1535-65.
35. Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol (2005) 19:833-42. doi:10.1210/me.2004-0486
36. Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med (2006) 27:299-402. doi:10.1016/j.mam.2006.07.001
37. Osmanbeyoglu HU, Lu KN, Oesterreich S, Day RS, Benos PV, Coronnello C, et al. Estrogen represses gene expression through reconfiguring chromatin structures. Nucleic Acids Res (2013) 41:8061-71. doi:10.1093/nar/gkt586
38. Acconcia F, Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett (2006) 238:1-14. doi:10.1016/j.canlet.2005.06.018
39. Chen JQ, Brown TR, Yager JD. Mechanisms of hormone carcinogenesis: evolution of views, role of mitochondria. Adv Exp Med Biol (2008) 630:1-18. doi:10.1007/978-0-387-78818-0_1
40. He YY, Cai B, Yang YX, Liu XL, Wan XP. Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Sci (2009) 100:1051-61. doi:10.1111/j.1349-7006.2009.01148.x
41. Roman-Blas JA, Castaneda S, Largo R, Herrero-Beaumont G. Osteoarthritis associated with estrogen deficiency. Arthritis Res Ther (2009) 11:241. doi:10.1186/ar2791
42. Lima LP, Barros IA, Lisboa PC, Araujo RL, Silva AC, Rosenthal D, et al. Estrogen effects on thyroid iodide uptake and thyroperoxidase activity in normal and ovariectomized rats. Steroids (2006) 71:653-9. doi:10.1016/j.steroids.2006.03.007
43. Furlanetto TW, Nguyen LQ, Jameson JL. Estradiol increases proliferation and down-regulates the sodium/iodide symporter gene in FRTL-5 cells. Endocrinology (1999) 140:5705-11. doi:10.1210/endo.140.12.7197
44. Rajoria S, Suriano R, Wilson YL, George AL, Geliebter J, Schantz SP, et al. Estradiol-mediated tumor neo-vascularization. Oncol Lett (2011) 2:453-7. doi:10.3892/ol.2011.283
45. Kouzmenko AP, Takeyama K, Ito S, Furutani T, Sawatsubashi S, Maki A, et al. Wnt/beta-catenin and estrogen signaling converge in vivo. J Biol Chem (2004) 279:40255-8. doi:10.1074/jbc.C400331200
46. Postiglione MP, Parlato R, Rodriguez-Mallon A, Rosica A, Mithbaokar P, Maresca M, et al. Role of the thyroid-stimulating hormone receptor signaling in development and differentiation of the thyroid gland. Proc Natl Acad Sci U S A (2002) 99:15462-7. doi:10.1073/pnas.242328999
47. Medina DL, Santisteban P. Thyrotropin-dependent proliferation of in vitro rat thyroid cell systems. Eur J Endocrinol (2000) 143:161-78. doi:10.1530/eje.0.1430161
48. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev (2001) 22:631-56. doi:10.1210/edrv.22.5.0444
49. Cass LA, Summers SA, Prendergast GV, Backer JM, Birnbaum MJ, Meinkoth JL. Protein kinase A-dependent and -independent signaling pathways contribute to cyclic AMP-stimulated proliferation. Mol Cell Biol (1999) 19:5882-91.
50. Roger PP, Van Staveren WC, Coulonval K, Dumont JE, Maenhaut C. Signal transduction in the human thyrocyte and its perversion in thyroid tumors. Mol Cell Endocrinol (2010) 321:3-19. doi:10.1016/j.mce.2009.11.015
51. Kursawe R, Paschke R. Modulation of TSHR signaling by posttranslational modifications. Trends Endocrinol Metab (2007) 18:199-207. doi:10.1016/j.tem.2007.05.002
52. Tallini G. Molecular pathobiology of thyroid neoplasms. Endocr Pathol (2002) 13:271-88. doi:10.1385/EP:13:4:271
53. Krohn K, Fuhrer D, Bayer Y, Eszlinger M, Brauer V, Neumann S, et al. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev (2005) 26:504-24. doi:10.1210/er.2004-0005
54. Matsuo K, Friedman E, Gejman PV, Fagin JA. The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs in human thyroid neoplasms. J Clin Endocrinol Metab (1993) 76:1446-51. doi:10.1210/jcem.76.6.8501149
55. Spambalg D, Sharifi N, Elisei R, Gross JL, Medeiros-Neto G, Fagin JA. Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. J Clin Endocrinol Metab (1996) 81:3898-901. doi:10.1210/jcem.81.11.8923835
56. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature (2005) 434:843-50. doi:10.1038/nature03319
57. Kim WB, Lewis CJ, Mccall KD, Malgor R, Kohn AD, Moon RT, et al. Overexpression of Wnt-1 in thyrocytes enhances cellular growth but suppresses transcription of the thyroperoxidase gene via different signaling mechanisms. J Endocrinol (2007) 193:93-106. doi:10.1677/JOE-06-0025
58. Chen G, Jiang Q, You Z, Yao J, Mou L, Lin X, et al. Regulation of GSK-3 beta in the proliferation and apoptosis of human thyrocytes investigated using a GSK-3 beta-targeting RNAi adenovirus expression vector: involvement the Wnt/beta-catenin pathway. Mol Biol Rep (2010) 37:2773-9. doi:10.1007/s11033-009-9819-5
59. Pascual A, Aranda A. Thyroid hormone receptors, cell growth and differentiation. Biochim Biophys Acta (2013) 1830:3908-16. doi:10.1016/j.bbagen.2012.03.012
60. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev (2010) 31:139-70. doi:10.1210/er.2009-0007
61. Yen PM, Ando S, Feng X, Liu Y, Maruvada P, Xia X. Thyroid hormone action at the cellular, genomic and target gene levels. Mol Cell Endocrinol (2006) 246:121-7. doi:10.1016/j.mce.2005.11.030
62. Keller H, Givel F, Perroud M, Wahli W. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol Endocrinol (1995) 9:794-804. doi:10.1210/mend.9.7.7476963
63. Banu SK, Govindarajulu P, Aruldhas MM. Developmental profiles of TSH, sex steroids, and their receptors in the thyroid and their relevance to thyroid growth in immature rats. Steroids (2002) 67:137-44. doi:10.1016/S0039-128X(01)00144-1
64. Kim WG, Cheng SY. Thyroid hormone receptors and cancer. Biochim Biophys Acta (2013) 1830:3928-36. doi:10.1016/j.bbagen.2012.04.002
65. Plateroti M, Kress E, Mori JI, Samarut J. Thyroid hormone receptor alpha1 directly controls transcription of the beta-catenin gene in intestinal epithelial cells. Mol Cell Biol (2006) 26:3204-14. doi:10.1128/MCB.26.8.3204-3214.2006
66. Kress E, Samarut J, Plateroti M. Thyroid hormones and the control of cell proliferation or cell differentiation: paradox or duality? Mol Cell Endocrinol (2009) 313:36-49. doi:10.1016/j.mce.2009.08.028
67. Kress E, Skah S, Sirakov M, Nadjar J, Gadot N, Scoazec JY, et al. Cooperation between the thyroid hormone receptor TRalpha1 and the WNT pathway in the induction of intestinal tumorigenesis. Gastroenterology (2010) 138:1863-74. doi:10.1053/j.gastro.2010.01.041
68. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol (2001) 158:987-96. doi:10.1016/S0002-9440(10)64045-X
69. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol (2011) 7:569-80. doi:10.1038/nrendo.2011.142
70. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science (2000) 289:1357-60. doi:10.1126/science.289.5483.1357
71. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol (2003) 21:3226-35. doi:10.1200/JCO.2003.10.130
72. Liu D, Yang C, Bojdani E, Murugan AK, Xing M. Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer. J Natl Cancer Inst (2013) 105:1617-27. doi:10.1093/jnci/djt249
73. Bellelli R, Castellone MD, Garcia-Rostan G, Ugolini C, Nucera C, Sadow PM, et al. FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocr Relat Cancer (2012) 19:695-710. doi:10.1530/ERC-12-0031
74. Nehs MA, Nucera C, Nagarkatti SS, Sadow PM, Morales-Garcia D, Hodin RA, et al. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology (2012) 153:985-94. doi:10.1210/en.2011-1519
75. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab (2013) 98:E1562-6. doi:10.1210/jc.2013-2383
76. De Felice M, Di Lauro R. Thyroid development and its disorders: genetics and molecular mechanisms. Endocr Rev (2004) 25:722-46. doi:10.1210/er.2003-0028
77. Fagman H, Nilsson M. Morphogenetics of early thyroid development. J Mol Endocrinol (2011) 46:R33-42. doi:10.1677/JME-10-0084
78. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 2:127-37. doi:10.1038/35052073
79. Konturek A. Thyroid growth factors. In: Ward DL, editor. Thyroid and Parathyroid Diseases - New Insight into Some Old and Some New Issues. InTech (2012). 318 p. doi:10.5772/37570
80. Kato S, Kobayashi T, Yamada K, Nishii K, Sawada H, Ishiguro H, et al. Expression of erbB receptors mRNA in thyroid tissues. Biochim Biophys Acta (2004) 1673:194-200. doi:10.1016/j.bbagen.2004.04.016
81. Bergstrom JD, Westermark B, Heldin NE. Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res (2000) 259:293-9. doi:10.1006/excr.2000.4967
82. Song B. Immunohistochemical demonstration of epidermal growth factor receptor and ceruloplasmin in thyroid diseases. Acta Pathol Jpn (1991) 41:336-43.
83. Schiff BA, Mcmurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res (2004) 10:8594-602. doi:10.1158/1078-0432.CCR-04-0690
84. Hoffmann S, Glaser S, Wunderlich A, Lingelbach S, Dietrich C, Burchert A, et al. Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors - a novel antiproliferative/antiangiogenic strategy in thyroid cancer. Langenbecks Arch Surg (2006) 391:589-96. doi:10.1007/s00423-006-0104-y
85. Lan L, Cui D, Nowka K, Derwahl M. Stem cells derived from goiters in adults form spheres in response to intense growth stimulation and require thyrotropin for differentiation into thyrocytes. J Clin Endocrinol Metab (2007) 92:3681-8. doi:10.1210/jc.2007-0281
86. Zheng X, Cui D, Xu S, Brabant G, Derwahl M. Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells. Int J Oncol (2010) 37:307-15. doi:10.3892/ijo_00000679
87. Malaguarnera R, Frasca F, Garozzo A, Giani F, Pandini G, Vella V, et al. Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol Metab (2011) 96:766-74. doi:10.1210/jc.2010-1255
88. Tseng LM, Huang PI, Chen YR, Chen YC, Chou YC, Chen YW, et al. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells. J Pharmacol Exp Ther (2012) 341:410-23. doi:10.1124/jpet.111.188730
89. Li W, Reeb AN, Sewell WA, Elhomsy G, Lin RY. Phenotypic characterization of metastatic anaplastic thyroid cancer stem cells. PLoS One (2013) 8:e65095. doi:10.1371/journal.pone.0065095
90. Ahn SH, Henderson YC, Williams MD, Lai SY, Clayman GL. Detection of thyroid cancer stem cells in papillary thyroid carcinoma. J Clin Endocrinol Metab (2014) 99:536-44. doi:10.1210/jc.2013-2558
91. Longmire TA, Ikonomou L, Hawkins F, Christodoulou C, Cao Y, Jean JC, et al. Efficient derivation of purified lung and thyroid progenitors from embryonic stem cells. Cell Stem Cell (2012) 10:398-411. doi:10.1016/j.stem.2012.01.019
92. Eggo MC, Hopkins JM, Franklyn JA, Johnson GD, Sanders DS, Sheppard MC. Expression of fibroblast growth factors in thyroid cancer. J Clin Endocrinol Metab (1995) 80:1006-11. doi:10.1210/jcem.80.3.7533768
93. Guo M, Liu W, Serra S, Asa SL, Ezzat S. FGFR2 isoforms support epithelial-stromal interactions in thyroid cancer progression. Cancer Res (2012) 72:2017-27. doi:10.1158/0008-5472.CAN-11-3985
94. Redler A, Di Rocco G, Giannotti D, Frezzotti F, Bernieri MG, Ceccarelli S, et al. Fibroblast growth factor receptor-2 expression in thyroid tumor progression: potential diagnostic application. PLoS One (2013) 8:e72224. doi:10.1371/journal.pone.0072224
95. Laron Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol Pathol (2001) 54:311-6. doi:10.1136/mp.54.5.311
96. Bendall SC, Stewart MH, Menendez P, George D, Vijayaragavan K, Werbowetski-Ogilvie T, et al. IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature (2007) 448:1015-21. doi:10.1038/nature06027
97. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, et al. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab (2002) 87:245-54. doi:10.1210/jcem.87.1.8142
98. Malaguarnera R, Belfiore A. The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. Front Endocrinol (Lausanne) (2014) 5:10. doi:10.3389/fendo.2014.00010
99. Jiang K, Yang Z, Cheng L, Wang S, Ning K, Zhou L, et al. Mediator of ERBB2-driven cell motility (MEMO) promotes extranuclear estrogen receptor signaling involving the growth factor receptors IGF1R and ERBB2. J Biol Chem (2013) 288:24590-9. doi:10.1074/jbc.M113.467837